Steven Elfrink, OmTerra Co-Founder and Psychedelic Somatic Interactional Therapist, is also the Co-Founder of the Psychedelic Somatic Institute (PSI), a psychedelic somatic therapist training organization. He was a participant in the 2015, Phase 1 FDA Pharmacokinetic Study of Psilocybin at UW-Madison that also studied the effects of high-dose psilocybin for adverse reactions. Steven had a first-hand experience of the benefits and shortcomings of the current non-directive model used in psychedelic therapy worldwide. This led him to creating OmTerra and PSI to expand the potential of psychedelic medicines utilizing a somatic focus. Steven brings 30 years of corporate experience in education and marketing to the psychedelic community and gratefully brings to the world his heart-felt passion for the advancement of psychedelic therapy and his commitment to help people who are suffering.